最近研究选择性抑制剂对odomain家族成员的进展和前景
Jianzhong Chen1, Yu'e Huang2, Jian Wang1
1School of Science, Shandong Jiaotong University, Jinan 250357, China.
Molecules (Basel, Switzerland)
|March 14, 2026
概括
含有odomain (BRD) 的蛋白质是关键的表观遗传药物标. 本综述强调了小分子抑制剂和基于BRD的治疗方法的计算研究的近期进展.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 药用化学 医学化学
- 计算生物学 计算生物学
背景情况:
- 含基因 (BRD) 的蛋白调节基因转录和染色质重塑.
- BRD与乙化氨酸残留物相互作用,使其成为关键的表观遗传点.
- 开发用于BRD的小分子抑制剂是药物发现的一个不断增长的领域.
研究的目的:
- 审查最近在小分子BRD抑制剂方面的突破.
- 讨论计算模拟在BRD抑制剂设计中的作用.
- 突出BRD抑制剂的生物影响和治疗潜力.
主要方法:
- 关于BRD抑制剂的最近研究的文献综述.
- 分析设计BRD向药物的计算方法.
- 综合了关于生物活动和治疗应用的发现.
主要成果:
- 在开发强效和选择性小分子BRD抑制剂方面取得了重大进展.
- 计算模拟在推进BRD抑制剂的设计和优化方面发挥了重要作用.
- 许多BRD抑制剂在各种疾病中显示出有前途的治疗潜力.
结论:
- 针对BRD蛋白的小分子抑制剂是一个有前途的治疗策略.
- 对抑制剂设计和计算方法的持续研究将加速药物开发.
- 本综述为未来针对BRD抑制剂的药物设计提供了指导.
更多相关视频
相关概念视频
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Eukaryotic Transcription Inhibitors
11.2K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.2K
Targets for Drug Action: Overview
11.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.0K
Dose-Response Relationship: Selectivity and Specificity
10.4K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
10.4K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.1K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.1K


